But Eli Lilly's Zepbound is best in class. Zepbound caused greater average weight loss than Wegovy in a head-to-head study.

Eli Lilly (LLY) has shown considerable rally potential, with several occurrences of its stock climbing over 30% in less than ...

Wall St. provides estimates for future stock prices of Eli Lilly from 2025 to 2030 based on projected revenue and net income.

Hyderabad: Global pharma heavyweights Eli Lilly and Novo Nordisk are racing to lock in market leadership in India’s blooming ...

Eli Lilly (NYSE:LLY) is rapidly establishing itself as the leader in GLP-1 treatments for weight loss. Its Zepbound injection ...

Eli Lilly also undertook 2-for-1 stock splits in 1995, 1989 and 1986. The company has been publicly traded since 1952.

Abivax (ABVX) stock surged on Obefazimod trial success and takeover rumors. Learn if valuation risks now outweigh reward.

As investors look beyond mega-cap tech for the next leg of growth, pharma is quietly moving back into focus — and no two ...

Eli Lilly's shares may appear expensive at first glance, but a closer look reveals a different story. The company's outlook is strong, and the stock is a buy, even at current levels. Eli Lilly's (NYSE ...

Novo Nordisk receives FDA approval for its oral weight-loss pill. Analyst says NVO stock might now have an edge over Eli Lilly.

Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...

U.S. Olympians Elana Meyers Taylor and Gabby Thomas participated in a social video, drawing a throughline between their ...